ClinicalTrials.gg
RecruitingNCT07681596Updated Oct 15, 2026

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

A Phase 1/2 interventional study of AZD4045 and Daratumumab in Relapsed or Refractory Multiple Myeloma, sponsored by AstraZeneca. Recruiting at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Primary conditionMultiple MyelomaRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Updated Oct 15, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
101
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Multiple Myeloma by AstraZeneca — 8 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · AstraZeneca.

Planned enrollment
9th of 16
101 · median 104
Started
2026
with 3 others
Phase 1/2
7 of 16
4 open now
Registered
14th of 16
by date

Among the 16 studies in Multiple Myeloma by AstraZeneca, this one is the 9th largest by planned enrollment, is one of 4 that started in 2026, is one of 7 in phase 1/2, and was the 14th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

8 of the 16 studies in Multiple Myeloma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Multiple Myeloma by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.

Read the detailed description

This modular study aims to evaluate the safety, tolerability, preliminary efficacy, and cellular kinetics of AZD4045 in participants with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose of AZD4045. Module 1 consists of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin.

03

Conditions studied

  • Relapsed or Refractory Multiple Myeloma

Browse trials for

Keywords

  • Multiple myeloma
  • Relapsed or refractory multiple myeloma
  • RRMM
  • Relapsed multiple myeloma
  • Refractory multiple myeloma
  • AZD4045
  • CAR-T
  • CART
  • Allogeneic
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's planned enrollment of 101 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 years or older at the time of signing the form.
  • Participants must have documented diagnosis of MM according to the IMWG diagnostic criteria.
  • Participant must have one or more of the following criteria:

    • Serum M-protein level ≥ 1.0 g/dL.
    • Urine M-protein ≥ 200 mg/24 h.
    • Serum immunoglobulin free light chain ≥ 10 mg/dL (100 mg/L) and abnormal serum immunoglobulin kappa lambda free light chain ratio.
  • performance score of 0 to 1.
  • Participant must have screening bone marrow aspirate and/or adequate for clonal sequence calibration for MRD. An archival sample obtained from any time prior is acceptable.
  • Participant must have adequate organ and bone marrow function.
  • Participant must have received at least 3 prior classes of therapy, including a PI, an IMiD, and an anti-CD38 antibody
  • Participant must have documented evidence of PD by IMWG 2016 criteria based on Investigator's determination during or after the most recent

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of any grade IEC-HS and/or history of Grade ≥ 3 CRS and/or Grade ≥ 2 neurotoxicities during prior CAR-T cell therapy or T cell engaging therapy.
  • Participant has ongoing toxicity from previous anti-cancer therapy that did not resolve to baseline levels or to Grade ≤ 1 with the exception of alopecia or peripheral neuropathy.
  • Participant has a known active, or prior history of CNS involvement or exhibits clinical signs of meningeal involvement of MM.
  • Participant has systemic immunoglobulin light chain amyloidosis, active plasma cell leukaemia (presence of ≥ 5% of circulating plasma cells on a conventional peripheral blood smear) at time of screening, Waldenstrom macroglobulinemia or Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin (POEMS) syndrome.
  • Participant has a history of haematologic , other than MM, regardless of remission status.
  • Participant has a history of a prior non-haematologic malignancy unless the participant has been disease-free with no evidence of recurrence for ≥ 2 years.
  • Participant has significant neurological or psychiatric condition (active or history of).
  • Participant is positive for any of the following:

    1. (with exceptions)
    2. Chronic or active
    3. Active
  • Participant has cardiovascular disease, including but not limited to:

    1. Myocardial infarction within 6 months prior to eligibility confirmation, or an unstable or uncontrolled disease/condition related to or affecting cardiac function.
    2. Uncontrolled cardiac arrhythmia or clinically significant abnormalities.
    3. Congestive heart failure Class III or IV.
    4. Impaired cardiac function ( \< 45%).
  • Participant has any other significant medical condition which, in the opinion of the Investigator, places the participant at an unacceptable risk for treatment-related complications, could interfere with the successful or safe delivery of therapy, or could interfere with evaluation of study intervention or interpretation of participant safety or study results. These include but are not limited to:

    1. Serious active or uncontrolled infection.
    2. Requirement of supplemental oxygen to maintain oxygen saturation.
    3. Active disease or a history of autoimmune disease within 2 years.
    4. Inflammatory bowel disease requiring treatment within the past 5 years or other clinically significant gastrointestinal condition.
  • Participant received live, attenuated vaccine within 28 days prior to eligibility confirmation
  • Participant has undergone major surgery within 28 days prior to eligibility confirmation
  • Concurrent enrolment in another clinical study (unless the study is observational, or the participant is in the follow-up period of an interventional study).
  • Participant has a known life-threatening allergy, , intolerance, or a to any study intervention or their .
  • Participant received any prior CAR-T or CAR-NK therapy directed at any target within 6 months prior to eligibility confirmation.
  • Participant received any prior TCE therapy directed at any target within 6 months prior to eligibility confirmation.
  • Participant received any prior BCMA-targeted treatment within 6 months prior to eligibility confirmation.
  • Participant with a history of refractoriness to the most recent BCMA-targeted treatment received as defined as PD on or within 60 days of last dose or non-responsiveness (ie, did not achieve at least minimal response) on therapy.
  • Participant received prior stem cell transplant at any time.
  • Participant received autologous stem cell transplant within 3 months prior to eligibility confirmation.
  • Participant received radiation therapy for treatment of plasmacytoma within 14 days before eligibility confirmation.
  • Participant received prior anti-tumour therapy as follows prior to the first dose of lymphodepletion:

    a) Within 7 days:

  • Immunomodulatory or cereblon E3 ligase modulatory drugs. b) Within 14 days:
  • PI therapy.
  • Monoclonal antibody treatment for MM.
  • Cytotoxic therapy.
  • Other systemic anti-myeloma therapy.
  • Radiation. c) Within 14 days or at least 5 half-lives, whichever is longer:
  • Targeted therapy, epigenetic therapy, drug or used an invasive investigational medical device.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (estimated)

Study arms

  • Experimental
    Module 1: AZD4045 monotherapy

    Biological: AZD4045

  • Experimental
    Module 1: AZD4045 in association with daratumumab and aldesleukin

    Biological: AZD4045 · Drug: Daratumumab · Drug: Aldesleukin

Interventions

  • BiologicalAZD4045

    Allogeneic Chimeric Antigen Receptor T cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA)

  • Anti-CD38 monoclonal antibody

  • Recombinant human IL-2

07

What researchers measure

Primary outcomes

  1. Adverse events (AEs) and serious AEs (SAEs)

    Incidence and severity of adverse events (AEs) and serious AEs (SAEs)

    Time frame: Through study completion, an average of 2 years

  2. Dose-limiting toxicities (DLT)

    Incidence and severity of dose-limiting toxicity (DLT) events

    Time frame: 28 days

Secondary outcomes

  1. Efficacy - Objective Response Rate (ORR)

    Defined as proportion of participants who achieve an overall response of PR or better according to the IMWG 2016 criteria

    Time frame: Through study completion, an average of 2 years

  2. Efficacy - Complete Response Rate (CRR)

    Defined as proportion of participants who achieve a CR/sCR response according to the to the IMWG 2016 criteria

    Time frame: Through study completion, an average of 2 years

  3. Efficacy - Duration of Response (DOR)

    Defined as the time from first documented confirmed response until date of documented PD per IMWG 2016 criteria or death due to any cause, whichever occurs first

    Time frame: Through study completion, an average of 2 years

  4. Efficacy - Time to Response (TTR)

    Defined as the time from infusion until the date of first documented objective response, as assessed per IMWG 2016 criteria

    Time frame: Through study completion, an average of 2 years

  5. Cellular kinetics - Quantification of CAR transgene levels

    Determination of transgene level

    Time frame: Through study completion, an average of 2 years

  6. Cellular kinetics - Tmax

    Time to reach maximum AZD4045 level

    Time frame: Through study completion, an average of 2 years

  7. Cellular kinetics - Cmax

    Maximum AZD4045 level

    Time frame: Through study completion, an average of 2 years

  8. Cellular kinetics - AUC0-28d

    Area under the concentration time-curve of AZD4045 level

    Time frame: 0 - 28 days

  9. Cellular kinetics - Tlast

    Time to last quantifiable concentration of AZD4045 level

    Time frame: Through study completion, an average of 2 years

  10. Cellular kinetics - Clast

    Observed concentration of AZD4045 at last quantifiable concentration

    Time frame: Through study completion, an average of 2 years

  11. Cellular kinetics - AUClast

    Area under the concentration time-curve of AZD4045 level

    Time frame: Through study completion, an average of 2 years

08

Study locations

3 of 12 sites recruiting
  • Research Site
    Duarte, California 91010, United States
    Recruiting
  • Research Site
    Denver, Colorado 80218, United States
    Not yet recruiting
  • Research Site
    Tampa, Florida 33612, United States
    Not yet recruiting
  • Research Site
    Atlanta, Georgia 30322, United States
    Not yet recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Not yet recruiting
  • Research Site
    Hackensack, New Jersey 07601, United States
    Not yet recruiting
  • Research Site
    Cleveland, Ohio 44195, United States
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Nashville, Tennessee 37203, United States
    Not yet recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Milwaukee, Wisconsin 53226, United States
    Withdrawn

    Not enrolling at this site.

  • Research Site
    Camperdown, 2050, Australia
    Not yet recruiting
  • Research Site
    East Melbourne, 3002, Australia
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2031, 55 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 55 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartActual
Jul 27, 2026
Primary completionEst.
Mar 6, 2031
CompletionEst.
Mar 6, 2031
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (2 now withdrawn, 1 now recruiting)
Show 3 sites
  • Research Site · Cleveland, United StatesNot yet recruiting→Withdrawn
  • Research Site · Houston, United StatesNot yet recruiting→Recruiting
  • Research Site · Milwaukee, United StatesNot yet recruiting→Withdrawn
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    3 sites changed recruiting status (2 now withdrawn, 1 now recruiting)
    Show 3 sites
    • Research Site · Cleveland, United StatesNot yet recruiting→Withdrawn
    • Research Site · Houston, United StatesNot yet recruiting→Recruiting
    • Research Site · Milwaukee, United StatesNot yet recruiting→Withdrawn
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07681596
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Jul 27, 2026
Primary completion
Mar 6, 2031 (estimated)
Completion
Mar 6, 2031 (estimated)
Last update
Oct 15, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion